Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab in CD55-Deficient PLE (CHAPLE Disease)
NCT04209634Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of pozelimab in CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy, sponsored by Regeneron Pharmaceuticals. Started Jan 2020; status: completed.
02
Drugs
pozelimab
03
Conditions
CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy
Beyond the preview
Go deeper on NCT04209634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209634.